TriSalus Life Sciences, Inc. (TLSI) stock
Close on Nov 11, 2026Market cap $141.62MP/E –Yield –
TriSalus Life Sciences, Inc. grew revenue 15.4% to $46.39M over the twelve months to Sep 30, 2026. Free cash flow was -$24.72M. At the latest close the market valued the company at $141.62M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $141.62M
- P/E ratio
- –
- Price to sales
- 3.05
- Price to book
- 208.27
- Dividend yield
- –
- Free cash flow yield
- -17.46%
Fundamentals
- Revenue
- $46.39M
- Net income
- -$26.26M
- EPS, diluted
- -$0.49
- Free cash flow
- -$24.72M
- Book value per share
- $0.01
- Diluted shares
- 58M
Trading
- Next earnings
- Mar 4, 2027 (estimated, after the close)
- Previous close
- $2.85
- Open
- $2.75
- Day's range
- $2.27 – $2.81
- Volume
- 913,548
- Average volume (20 days)
- 256,533
- Index membership
- Russell 2000 (since Jun 2025)
- Beta (5 years)
- 0.56
- 52-week range
- $2.20 – $7.95
- RSI (14 days)
- 22.5
- Volatility (1 year)
- 83.5%
- Relative volume
- 3.47×
- WACC
- 8.4%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | TLSI | S&P 500 | Difference | TLSI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -43.3% | -2.4% | −40.9 pts | ||
| 3 months | -59.9% | -1.2% | −58.8 pts | ||
| Year to date | -67.0% | +12.3% | −79.3 pts | ||
| 1 year | -47.0% | +12.4% | −59.5 pts | ||
| 3 years | -42.4% | +78.8% | −121.2 pts | -16.8% | +21.4% |
| 5 years | -76.9% | +75.2% | −152.1 pts | -25.4% | +11.9% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases TriSalus Life Sciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Results
- Results
- Update
- Results
About TriSalus Life Sciences
Surgical & Medical Instruments & Apparatus
TriSalus Life Sciences, Inc. is an oncology-focused medical technology company that develops drug delivery systems and investigational therapeutics for treating solid tumors. Its primary commercial product is the TriNav Infusion System, which utilizes Pressure-Enabled Drug Delivery technology and SmartValve mechanisms to overcome high intratumoral pressure during interventional embolization procedures. The business operates across delivery device technology and investigational immunotherapy segments, including development of nelitolimod and the Pancreatic Retrograde Venous Infusion system. Its direct customers comprise hospital value analysis committees, interventional radiologists, medical oncologists, and related clinical support personnel.
Company profile, executives and historyTriSalus Life Sciences stock: common questions
What is TriSalus Life Sciences's stock price?
TLSI closed at $2.30 on Nov 11, 2026, down 19.30% on the day. Over the past 52 weeks it traded between $2.20 and $7.95.
What is TriSalus Life Sciences's market cap?
TriSalus Life Sciences was worth $141.62M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is TLSI's P/E ratio?
TriSalus Life Sciences lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.49), so it has no meaningful P/E ratio.
How much revenue does TriSalus Life Sciences make?
TriSalus Life Sciences reported revenue of $46.39M for the twelve months to Sep 30, 2026, up 15.4% from a year earlier.
Does TriSalus Life Sciences pay a dividend?
No. TriSalus Life Sciences has not paid a cash dividend over the last twelve months.
When does TriSalus Life Sciences report earnings next?
TriSalus Life Sciences is expected to report Q4 FY2026 results on Mar 4, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has TLSI stock performed over the past year?
Including dividends, TLSI returned -47.0% over the past year, against +12.4% for the S&P 500.
Who are TriSalus Life Sciences's competitors?
Companies most similar to TriSalus Life Sciences by business, industry and size include DCTH, SI, CLPT, KRMD, SNWV.
See a number that looks wrong?